#CPX351 - Twitter Hashtag

血液内科医　中村　幸嗣

@yukitsugu1963

2 months ago

状況により赤字になる急性骨髄性白血病治療 #CPX351 #DPC

0

3

0

423

Aref Al-Kali

@AlkaliDr

5 months ago

Molecular grouping of pts treated with #CPX351 vs #7+3 ⭐️ randomised study in #AML_mrc ⭐️ benefit for CPX mainly in AML-mr but not p53m or other cases ⭐️DDD41 did well c CPX but small N ⭐️benefit HCT mainly in aml-mr ⁦@BloodAdvances⁩ https://t.co/k9PoTVYlMC

0

18

3

10

1K

Oncology Brothers

@OncBrothers

8 months ago

Data in hand that we touched on #CPX351 during our discussion with @Daver_Leukemia! - mOS: 9.6mos vs. 6mos (HR: 0.69) - 5yr OS: 18% vs. 8% - Is #PARADIGM (HMA+Ven) going to challenge this? Need bigger/more mature data here. #HemeTwitter #MedX #OncTwotter #leusm @OncUpdates

OncBrothers's tweet photo. Data in hand that we touched on #CPX351 during our discussion with @Daver_Leukemia!

- mOS: 9.6mos vs. 6mos (HR: 0.69)
- 5yr OS: 18% vs. 8%
- Is #PARADIGM (HMA+Ven) going to challenge this? Need bigger/more mature data here.

#HemeTwitter #MedX #OncTwotter #leusm @OncUpdates https://t.co/8J9gzPfSXC

Oncology Brothers

@OncBrothers

8 months ago

In our “Challenging Case” discussion w/ @Daver_Leukemia we touched on front line treatment for AML: ✅ CPX-351 vs. 7+3 ✅ HMA + Ven ✅ AEs & management Full 🗣️: ⭐️ On OncBrothers & OncUpdates Website ⭐️ “Oncology Brothers” podcast #HemeTwitter @OncUpdates @OncoAlert

0

28

3

6

11K

0

8

5

1

3K

Oncology Brothers

@OncBrothers

almost 2 years ago

#ASH24 #Leukemia Highlights w/ @beatalleukemia - #KOMET007 - #CPX351 - #Venetoclax + Induction Full 📢: - https://t.co/wwo9Lfd9pq - https://t.co/uId0JSrSk0 - Also on “Oncology Brothers” podcast #MedTwitter #HemeTwitter #leuksm @TargetedOnc #OncTwitter @ASH_hematology

0

17

7

6

6K

Aref Al-Kali

@AlkaliDr

almost 2 years ago

A sub analysis of UK NCRI AML19 study comparing #CPX351 vs #FLAGida in pts with #MDS related mutations ⬆️ CR in FLAGida ⬆️ OS in CPX351 ⬆️ HCT in CPX351 #ASH24 #Amlsm

AlkaliDr's tweet photo. A sub analysis of UK NCRI AML19 study comparing #CPX351 vs #FLAGida in pts with #MDS related mutations
⬆️ CR in FLAGida
⬆️ OS in CPX351
⬆️ HCT in CPX351

#ASH24
#Amlsm https://t.co/nh7KIkx3KG

0

2

0

1

271

Aref Al-Kali

@AlkaliDr

almost 3 years ago

#CPX351 in r/r #MDS 👉🏻 dose 50 ARAc 👉🏻 ORR 50% Phase 1/2 study of CPX‐351 for patients with Int‐2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents https://t.co/4d98PYBdAp

0

4

1

666

Naveen Pemmaraju, MD @doctorpemm

almost 3 years ago

👉👉👉Brand new paper alert 🚨 from our group led by Dr .@GMontalbanBravo & Dr GGM @garciamanero ➡️ #CPX351 for patients with HR MDS & CMML s/p HMA | @BrJHaem @MDAndersonNews #leusm #CMMLsm #MDSsm #endcancer | @DrHKantarjian @sanamloghavi @doctorpemm https://t.co/8Sh0r69K8V |

2

33

3

4

4K

SpringerMedizin.at

@SpringerMed

over 3 years ago

Wie wird Menschen mit #akuter #myeloischer #Leukämie, kurz #AML, heute geholfen? Darüber spricht Martin Krenek-Burger im #Hörgang #Podcast mit Dr. Sigrid Machherndl-Spandl und mit Dr. Elisabeth Koller. #CPX351 #sciencestattfiction https://t.co/eeFDc8xeRD?

0

1

0

102

CHU de Nice @CHUdeNice

over 5 years ago

#Research on #hematology 📰"Real-life experience with #CPX351 and impact on the outcome of high-risk #AcuteMyeloidLeukemia #AML patients: a multicentric French cohort" by Pr @thomas_cluzeau and Dr Edmond Chiche from #CHUdeNice. https://t.co/uc1en1iw9b

1

6

2

0

Naveen Pemmaraju, MD @doctorpemm

almost 6 years ago

#ASH20 | @TapKadia et al Ph2 #CPX351 + #Venetoclax in patients with AML https://t.co/VI8yGHWyoz | #leusm @DrKTakahashi @doctorpemm @Daver_Leukemia @NitinJainMD @garciamanero #endcancer @LeukemiaMDA

doctorpemm's tweet photo. #ASH20 | @TapKadia et al Ph2 #CPX351 + #Venetoclax in patients with AML https://t.co/VI8yGHWyoz | #leusm @DrKTakahashi @doctorpemm @Daver_Leukemia @NitinJainMD @garciamanero #endcancer @LeukemiaMDA https://t.co/miuJopwHty

0

22

5

0

Moffitt Cancer Center

@MoffittNews

almost 7 years ago

Dr. Jeffrey E. Lancet of @MoffittNews highlights outcomes in patients with therapy-related AML who achieved remission with #CPX351 versus 7+3. #ASH19 #AML Full abstract: https://t.co/vmxThXUSNL

1

13

4

0

David Steensma, MD @DavidSteensma

almost 7 years ago

My man ⁦@ColemanLindsley⁩ making us ⁦@DanaFarber⁩ proud 😊: #ASH19 #AML molecular analysis of JLancet et al randomized #CPX351 vs 3&7 sAML trial. No molecular subgroup did better w/ one arm vs the other. #TP53 (33% of patients) is crappy whether you get CPX351 or 3&7

DavidSteensma's tweet photo. My man ⁦@ColemanLindsley⁩ making us ⁦@DanaFarber⁩ proud 😊: #ASH19 #AML molecular analysis of JLancet et al randomized #CPX351 vs 3&7 sAML trial. No molecular subgroup did better w/ one arm vs the other. #TP53 (33% of patients) is crappy whether you get CPX351 or 3&7 https://t.co/HNCSfvcdpu

2

69

16

1

0

David Steensma, MD @DavidSteensma

almost 7 years ago

Fellow #AML / #MDS doctors - asking for a patient: have you ever had a patient get all the way through a #CPX351 induction begun as an outpatient without being hospitalized eg for F&N? My latest patient is proud of setting institutional “record” getting to day 20 @calliecoombsmd

9

36

3

0